REFRACTORY ACUTE MYELOID LEUKEMIA

This study tests a combination of two drugs, enasidenib and azacitidine, for people with a specific genetic form of acute myeloid leukemia (IDH2-mutated) that has come back or stopped responding to treatment. The goal is to see if the combo can shrink or control the cancer. About…

This study tests a new approach for adults with aggressive blood cancers (like AML) that are hard to treat. Patients get a stronger chemotherapy mix (decitabine plus FLAG-Ida) and total body radiation, followed by a donor stem cell transplant. The goal is to kill cancer cells and…

This study is for adults with certain blood cancers (like acute myeloid leukemia) that have come back or not responded to standard treatment. Participants receive a strong chemotherapy combination (CLAG-M or FLAG-Ida) followed immediately by a stem cell transplant from a donor. T…

This early-stage study tests a new daily pill, BH-30236, in adults whose acute myeloid leukemia or high-risk myelodysplastic syndrome has returned or stopped responding to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink ca…

This early-stage study tests a new drug, AOH1996, in 12 adults whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The main goals are to find a safe dose and check for side effects. AOH1996 works by blocking a protein that cancer cells need to…

This study tests a combination of four chemotherapy drugs (cladribine, idarubicin, cytarabine, and venetoclax) in about 500 adults with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blast-phase chronic myeloid leukemia. The goal is to see how well these drugs kil…

This study tests a combination of three drugs (azacitidine, venetoclax, and gilteritinib) in people with certain blood cancers that have a FLT3 mutation. The goal is to find the safest dose and see if the combo works better than standard treatments. The study includes adults whos…

This study tests a radioactive antibody (211At-BC8-B10) given before a donor stem cell transplant for people with high-risk leukemias or related blood cancers. The antibody targets cancer cells and delivers radiation to help kill them while sparing healthy cells. The goal is to f…

This study tests a combination of two drugs, CPX-351 and ivosidenib, in about 30 people with a specific genetic form of acute myeloid leukemia or a related high-risk bone marrow disorder. The goal is to see if the combo can shrink or control the cancer. Participants must have the…

This early-stage study tests a new treatment called CER-1236 for people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, or myelofibrosis) that have not responded to standard therapy. CER-1236 is made from a patient's own immune cells, which are modif…

This study tests a combination of tagraxofusp and two chemotherapy drugs (cladribine and cytarabine) for people with a type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial includes 20 adults whose cancer cells have a specific marker cal…

This study is testing a combination of three drugs—quizartinib, decitabine, and venetoclax—in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. The goal is to see if the combination can shrink or control the cancer. The trial is for adults 60 and old…

This study tests a combination of two drugs, CPX-351 and venetoclax, in adults with acute myeloid leukemia (AML) that has returned, not responded to treatment, or is newly diagnosed. The goal is to see if the combo can stop cancer growth and achieve remission. About 52 participan…

This study tests a drug called Vyxeos in adults with acute myeloid leukemia (AML) whose cancer did not go away after the first round of standard chemotherapy. Vyxeos combines two common chemo drugs inside a tiny fat bubble (liposome) to deliver them more directly to cancer cells,…

This early-phase study tests whether combining two targeted drugs, SNDX-5613 and gilteritinib, is safe and effective for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The leukemia must have a FLT3 gene mutation plus e…

This study tests whether adding the drug venetoclax to standard chemotherapy can better treat acute myeloid leukemia (AML), a fast-growing blood cancer. About 116 adults with newly diagnosed or returning AML will receive the combination. The goal is to see if the combo improves r…

This early-stage study tests a combination of two drugs, bomedemstat and venetoclax, in adults with acute myeloid leukemia (AML) that has returned or not responded to prior therapy. The main goal is to find the safest dose and understand side effects. About 18 participants will b…

This study is for people with certain blood cancers (like leukemia) that have a specific genetic change called an IDH1 mutation. It tests a combination of two or three drugs: ivosidenib (targets the mutation), venetoclax (blocks a protein that helps cancer cells survive), and som…

This early-stage study tests a three-drug combination (ruxolitinib, azacitidine, and venetoclax) in adults with acute myeloid leukemia that has come back or not responded to prior therapy. The main goal is to find the safest dose and see if the combination helps control the cance…

This study tests a combination of three drugs (ASTX727, venetoclax, and either ivosidenib or enasidenib) in people with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see if this mix is safe and can shrink or control the cancer. About 84 a…

This early-phase study tests the safety and best dose of a new drug, miRisten, in 12 adults with acute myeloid leukemia (AML) that has come back or not improved after standard treatments. The drug works by blocking certain molecules that help cancer cells grow. The main goal is t…

This study tests adding venetoclax to a standard chemotherapy regimen (CLAG-M) for people with acute myeloid leukemia (AML) or related high-grade blood cancers. The goal is to find the safest dose and see if the combination improves cancer control. About 62 participants will be e…

This early-phase study tests a new treatment for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack leukemia cells. The main goals…

This early-phase trial tests a combination of three drugs (pembrolizumab, decitabine, and venetoclax) in adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or not responded to prior treatment. The goal is to find the safest dose and see how well the …

This early-stage study tests whether drugs that remove extra metals from the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. Researchers want to find the safest dose and see if lowering metal levels in blood…

This early-phase trial tests a new treatment for adults with acute myeloid leukemia (AML) that has returned or not responded to standard therapy. The treatment uses specially engineered immune cells (CD83 CAR T cells) designed to find and destroy leukemia cells while possibly avo…

This study tests an oral drug called ONC201 in adults whose acute leukemia or high-risk myelodysplastic syndrome (MDS) has come back or stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink or control the cancer. About 120 p…

This study tests a combination of two drugs—CPX-351 (a stronger form of standard chemo) and quizartinib (a targeted therapy)—in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The goal is to find the safest dose and see if the combo can bette…

This early-stage study tests a new drug called cirtuvivint, alone or with another drug (ASTX727), in people with certain blood cancers (MDS and AML). The goal is to find a safe dose and see how well it works. About 54 adults whose cancer has returned or not responded to treatment…

This study tests a combination of four drugs (cladribine, idarubicin, cytarabine, and quizartinib) in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that is either newly diagnosed or has returned/not responded to treatment. The goal is to see…

This study tests whether adding a new drug called revumenib to two standard chemotherapy drugs (azacitidine and venetoclax) is safe for children and young adults whose acute myeloid leukemia (AML) has not responded to treatment or has returned. About 24 participants will receive …

This early-stage trial tests the safety and best dose of an oral drug (ASTX727) plus a growth factor (filgrastim) in children with high-risk acute myeloid leukemia (AML) who have already had a stem cell transplant. The goal is to see if this maintenance therapy can help prevent t…

This study tests a combination of three drugs (ASTX727, venetoclax, and gilteritinib) for people with acute myeloid leukemia or high-risk myelodysplastic syndrome that has a specific gene change called FLT3. The goal is to find the best dose and see how well the drugs work togeth…

This early-phase study tests a new treatment called CD371-YSNVZ-IL18 CAR T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goal is to find the safest dose and see what side effects occur. About 15 participants w…

This early-phase study tests two different drug combinations for people whose acute myeloid leukemia has returned or not responded to prior treatment. The goal is to find safer and more effective ways to control the disease. About 24 adults will participate, receiving either taze…

This early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is des…

This early-stage study is testing a new treatment called LILRA6 CAR-T for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack …

This study tests a radioactive antibody (211At-BC8-B10) followed by a donor stem cell transplant for people with high-risk leukemia or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The antibody targets cancer cells and delivers radiation, then c…